Enanta Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

21.04.17	Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C (PR Newswire)
20.04.17	AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis (PR Newswire)
14.03.17	AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C (PR Newswire)
27.02.17	AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic... (PR Newswire)
02.02.17	U.S. FDA Grants Priority Review to AbbVie for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) (PR Newswire)
24.01.17	European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie's Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of... (PR Newswire)
09.01.17	Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR[12] Rates in Genotype 1... (PR Newswire)
19.12.16	AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C (PR Newswire)
26.07.16	FDA Oks AbbVie' VIEKIRA XR To Treat Genotype 1 Chronic Hepatitis C Virus (RTTNews)
18.04.16	FDA Snubs CHMA, NICE Is Nice With PTCT, RXII To Effect Reverse Split (RTTNews)
16.04.16	NY Attorney General Sues CDPHP For Unlawfully Denying Coverage Of HCV Treatment (RTTNews)
16.04.16	AbbVie: New Data Shows Potential Of ABT-493, ABT-530 In Hepatitis C Genotypes (RTTNews)
14.11.15	AbbVie: VIEKIRA PAK Achieves 95% Sustained Virologic Response Rates In TOPAZ-II (RTTNews)
28.09.15	Enanta Announces Approval Of AbbVie's Viekirax In Japan For Chronic Hepatitis C (RTTNews)
25.04.15	AbbVie Presents Preliminary Phase 3b Data With VIEKIRAX + EXVIERA (RTTNews)
16.04.15	AbbVie's Chronic Hepatitis C Treatment Granted Priority Review In Japan (RTTNews)
02.02.15	Enanta Pharma: Phase 3 GIFT-1 Study Achieves Primary Endpoint - Quick Facts (RTTNews)
16.01.15	Enanta Pharma: EC Grants Marketing Authorizations For AbbVie's VIEKIRAX (RTTNews)
22.12.14	JAZZ Hits Right Note, ENTA's Purse Set To Fatten, AEZS Put On Notice (RTTNews)
20.12.14	FDA Okays AbbVie's Viekira Pak To Treat Hepatitis C (RTTNews)
24.11.14	Enanta Pharma Loss Narrower Than Estimates, Revenue Misses (RTTNews)
21.10.14	Enanta Not To Exercise Co-development Option For ABT-493 - Update (RTTNews)
21.10.14	Enanta Not To Exercise Co-development Option For ABT-493 (RTTNews)
02.10.14	ARDX Surges On Study Data, HBIO Opens Wallet, ZGNX On Watch, PTLA Creates Buzz (RTTNews)
23.04.14	QRxPharma Snubbed Again, Illumina Shines, ENTA Gets Rich, LLY Opens Wallet (RTTNews)
22.04.14	Enanta Pharma Announces NDA Submission To FDA For Hepatitis C Treatment (RTTNews)
31.01.14	Pre-market Movers For Jan 31 (GOOG, AMZN, WMT, ENTA, ZNGA, MAT, DLLR) (RTTNews)
31.01.14	Enanta Announces Results From Four All-Oral, Interferon-Free, Phase 3 Studies (RTTNews)
11.12.13	AVNR's PRIME Flops, BG Medicine Tastes Sweet, CYTR Awaits Data, ENTA Shines (RTTNews)
10.12.13	Enanta Pharmaceuticals Announces Results From SAPPHIRE-II Study - Quick Facts (RTTNews)
25.11.13	Enanta Pharma Q4 Loss Narrows (RTTNews)
19.11.13	CRME Opens Wallet, CGIX Launches FHACT, ENTA's SAPPHIRE Sparkles, IPCI Explodes (RTTNews)
03.11.13	Enanta Pharma Presents Addl. Data From AbbVie's M13-393 Study (RTTNews)
25.09.13	Drug Approvals, Data Presentations, Conferences, Increased Funding, and Merger Agreements - Research Report on Theravance, Arena, Exelixis, Verenium, and Enanta (PR Newswire)
04.09.13	RMTI Awaits CRUISE-2, AVNR On A High, ENTA Gets More Funds, Watch Out For ZLCS (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Enanta Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten